Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

Published:2023-03 Issue: Volume:170 Page:38-45
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Mauricio Dennis,Bellone Stefania,Mutlu Levent,McNamara Blair,Manavella Diego D.,Demirkiran Cem,Verzosa Miguel Skyler Z.,Buza Natalia,Hui Pei,Hartwich Tobias Max Philipp,Harold Justin,Yang-Hartwich Yang,Zipponi Margherita,Altwerger Gary,Ratner Elena,Huang Gloria S.,Clark Mitchell,Andikyan Vaagn,Azodi Masoud,Schwartz Peter E.,Santin Alessandro D.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference28 articles.

1. Uterine carcinosarcoma;Arend;Curr. Opin. Oncol.,2011

2. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy;Rottmann;Mod. Pathol.,2020

3. The impact of multi-modal therapy on survival for uterine carcinosarcomas;Gonzalez Bosquet;Gynecol. Oncol.,2010

4. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis;Rauh-Hain;Gynecol. Oncol.,2013

5. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome;George;Gynecol. Oncol.,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment;Molecular Pharmaceutics;2024-02-12

2. Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report;Gynecologic Oncology Reports;2023-12

3. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors;Molecules;2023-11-02

4. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma;American Journal of Clinical Oncology;2023-10-17

5. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma;Molecular Cancer Therapeutics;2023-09-07